Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAXAIR vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Prevention and treatment of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via glucuronidation and sulfate conjugation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
55–70%, primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
2.0–2.5 L/kg; indicates extensive distribution into tissues.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: approximately 20–30% of the delivered dose reaches the systemic circulation; oral bioavailability is <1% due to first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific dose adjustment required; medication is primarily hepatically metabolized.
No dose adjustment required for renal impairment.
No specific dose adjustment guidelines; use caution in severe hepatic impairment due to potential decreased drug clearance.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Children 6-11 years: 1-2 inhalations (170-340 mcg) via oral inhalation every 4-6 hours as needed; maximum 8 inhalations per day. Children ≥12 years: same as adult.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
No specific dose adjustment; monitor for increased sensitivity to beta-agonists (e.g., tachycardia, tremor) and concurrent diseases (e.g., cardiovascular disorders).
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA boxed warning.
No FDA black box warning exists for this drug.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to pirbuterol or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No specific food interactions. Avoid excessive caffeine intake as it may increase stimulant effects. Grapes, grapefruit, and grapefruit juice have no significant interaction with pirbuterol.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/day in rats and up to 10 mg/kg/day in rabbits, but fetal growth retardation and increased mortality were observed at maternally toxic doses. Risk to human fetus cannot be ruled out. Use during pregnancy only if potential benefit justifies potential risk.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Unknown if pirbuterol is excreted in human milk. Due to lack of data and potential for serious adverse reactions in nursing infants, caution is advised. M/P ratio not determined.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific pharmacokinetic data in pregnancy; standard dosing recommended. Beta-agonists may delay preterm labor; use with caution.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
MAXAIR (pirbuterol) is a beta-2 adrenergic agonist for asthma and COPD. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, or hypertension. Monitor for paradoxical bronchospasm; if occurs, discontinue immediately. Not indicated for acute severe asthma exacerbations unless patient is closely monitored. Can cause hypokalemia, especially with concomitant use of corticosteroids or diuretics. Administer with a spacer device to improve lung deposition and reduce oral side effects.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Use only as prescribed; do not exceed recommended doses.,Rinse mouth after inhalation to prevent oral thrush.,Contact doctor if symptoms worsen or if you need more than usual doses.,Do not share the inhaler; keep it clean.,Seek immediate medical help if you experience chest pain, rapid heartbeat, or severe wheezing after use.,Inform your doctor if you have heart disease, high blood pressure, seizures, or diabetes.,Avoid using with other asthma medications without consulting your doctor.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAXAIR vs AEROLATE SR, answered by our medical review team.
MAXAIR is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAXAIR and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAXAIR is: 2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAXAIR and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAXAIR is classified as Category C. FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/da. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.